Plasma Ang II levels were found to be significantly higher in the tumor-bearing vehicle-treated group compared to the tumor-free vehicle-treated mice (2.7 ± 0.3 ng/ml compared to 1.00 ± 0.34 ng/ml, p < 0.0001) (Fig 5A). This evidence concerns the gene AGT and neoplasm.